Investing
Regeneron beats quarterly profit estimates
© Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid/File Photo
(Reuters) – Regeneron Pharmaceuticals Inc (NASDAQ:) beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent.
Excluding items, the company reported a profit of $10.09 per share for the quarter, above analysts’ estimates of $9.56, according to Refinitiv data.
(This story has been corrected to remove reference to Eylea in the headline and paragraph 1)
Read the full article here
-
Side Hustles6 days ago
Microsoft Is About to Begin Job Cuts. Here’s Why.
-
Make Money5 days ago
10 Critical Questions to Ask Your Financial Advisor Now
-
Make Money4 days ago
10 Ways to Make Money As a Graphic Designer
-
Passive Income7 days ago
3 Challenges Entrepreneurs Will Face in 2025
-
Investing6 days ago
What CMOs Need to Know About AI Adoption in Marketing Teams
-
Side Hustles7 days ago
The Canadian Media Lawsuit That Could Reshape Tech’s Future
-
Personal Finance3 days ago
If you are 60 years old, new 401(k) rules could save you money
-
Side Hustles6 days ago
JPMorgan to Implement a Five-Day Return-to-Office Mandate